ArticleMolecular cancer therapeutics2024

Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules.

Andreas Gollner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.